Review of Biologics in Children With Rheumatic Diseases

Shabina Habibi; Athimalaipet V Ramanan

Disclosures

Int J Clin Rheumatol. 2012;7(1):81-93. 

In This Article

Canakinumab

Canakinumab is a human IL-1β antibody that binds to IL-1β, blocking its activity. It has a long plasma half-life and is administered at a dose of 4 mg/kg subcutaneously once a month. In a Phase II dose-escalation trial, 23 children were treated with canakinumab, in doses ranging from 0.5 to 9 mg/kg.[41] Seventeen of them had been previously treated with anakinra. A total of 59% of the children reached ACR-Pedi 50 response within 15 days, and 18% achieved inactive disease. Six out of 11 nonresponders to anakinra, responded to a single dose of canakinumab. A randomized, placebo-controlled double-blind study of monthly subcutaneous injection of canakinumab is currently underway.[103]

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....